Queen's University at Kingston
- Country
- 🇨🇦Canada
- Ownership
- Private
- Established
- 1841-10-16
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.queensu.ca
Clinical Trials
315
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (290 trials with phase data)• Click on a phase to view related trials
Evaluating Simulation Experiences to Help Navigate Racism and Hidden Bias
- Conditions
- Implicit Bias
- First Posted Date
- 2025-07-31
- Last Posted Date
- 2025-07-31
- Lead Sponsor
- Queen's University
- Target Recruit Count
- 450
- Registration Number
- NCT07095335
- Locations
- 🇨🇦
Queen's University, Kingston, Ontario, Canada
Infection, Prevention and Control: A Multifaceted Approach to Preventing Hospital Acquired Infections Principal
- Conditions
- Infection Prevention
- First Posted Date
- 2025-07-24
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- Queen's University
- Target Recruit Count
- 50
- Registration Number
- NCT07083024
- Locations
- 🇨🇦
Queen's University, Kingston, Ontario, Canada
A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.
- Conditions
- NMIBCNon-Muscle Invasive Bladder Urothelial CarcinomaBladder (Urothelial, Transitional Cell) CancerUrothelial Carcinoma Bladder
- Interventions
- Drug: Gemcitabine + BCGDrug: BCG (TICE strain)
- First Posted Date
- 2025-07-15
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- Queen's University
- Target Recruit Count
- 31
- Registration Number
- NCT07064863
- Locations
- 🇨🇦
Kingston Health Sciences Center, Kingston, Ontario, Canada
Bone Enhanced Ultrasound (BEUS) Data Library Development Project
- Conditions
- Lower Back PainFacet Joint Pain; Low Back PainOsteoarthritis (OA)
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-07-29
- Lead Sponsor
- Queen's University
- Target Recruit Count
- 100
- Registration Number
- NCT07036653
Vaginal Estrogen for Improvement of Outcomes Following Pelvic Organ Prolapse Surgery
- Conditions
- Pelvic Organ Prolapse (POP)
- Interventions
- Drug: Vaginal Estrogen - Twice WeeklyDrug: Vaginal Estrogen - Daily
- First Posted Date
- 2025-06-22
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Queen's University
- Target Recruit Count
- 180
- Registration Number
- NCT07030426
- Locations
- 🇨🇦
Health Sciences Centre, St John's, Newfoundland and Labrador, Canada
🇨🇦Kingston Health Sciences Centre, Kingston, Ontario, Canada
- Prev
- 1
- 2
- 3
- 4
- 5
- 63
- Next
News
World-First Clinical Trial Demonstrates Exercise Significantly Improves Colon Cancer Survival
A groundbreaking 17-year international clinical trial involving 889 colon cancer patients shows that structured exercise programs reduce cancer recurrence risk by 28% and death risk by 37%.
myeloMATCH Trials Open to Accelerate Precision Medicine for AML and MDS
myeloMATCH, a collaborative effort by leading cancer research organizations, launches clinical trials to advance precision medicine for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Stepped Care Model Shows Promise in Enhancing Adherence to Internet-Based CBT for Depression
A recent study investigated the efficacy of a stepped care model combined with internet-based cognitive behavioral therapy (i-CBT) for adults with major depressive disorder (MDD).